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Aim: To summarize the follow-up of children who underwent orthotopic heart
transplantation (HTx) in the Center of Cardiovascular and Transplantation Surgery
in Brno during the past 17 years.
Patients and methods: Between May 1995 and October 2012, 42 children aged 2
months–17.5 years were listed for HTx, of these 26 underwent HTx later.
Results: Of 42 children listed for HTx, 12 died, 26 underwent HTx, 3 were excluded because of
improved clinical status, and 1 is waiting for HTx. Five children died early after the
transplantation, one patient died 6.5 years after HTx. The 1-year, 5-years and 10-years post-
transplantation survival rates are 81%, 81%, and 76.9%, respectively. One patient underwent
re-transplantation 11.5 years after HTx because of coronary artery disease affecting the graft.
Long-term follow-up data are available for 21 children surviving 1.6–17.4 years (mean 8.775.3
years). The most common morbidities were hypertension and mild chronic kidney disease
(CKD 2). Pneumonia was the most common infectious complication requiring hospitalization.
EBV infection with subsequent development of post-transplant lymphoproliferative disorder
(PTLD) was a severe late complication in two patients (diagnosed 8 and 15 years after
transplantation). The increase in incidence of coronary artery disease during the second decade
post-HTx (affecting 7.7% patients after 5 years and 42.8% patients after 10 years) leads to a
signiﬁcant increase in the morbidity of pediatric patients surviving more than 10 years after
transplantation.
Conclusion: Heart transplantation currently represents an effective treatment of terminal heart
failure in children. Improving outcomes of pediatric HTx mainly reﬂect the drop in early
mortality. The main causes of late morbidity and mortality of children after HTx are the
increase in incidence of coronary artery disease and malignant diseases (PTLD). Our results of
long-term follow-up of children after heart transplantation are consistent with published data
from other centers.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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The ﬁrst pediatric heart transplantation (HTx), was per-
formed in a newborn with severe form of Ebstein anomaly,
in New York by Kantrowitz on December 6th, 1967 [1].
Improved care of the donors, deﬁnition of indication criteria,
advances in the perioperative care and development of new
immunosuppressive agents all resulted in decrease of early
mortality and improved survival of pediatric recipients. How-
ever late mortality, mainly caused by coronary graft disease
with graft failure and of post-transplant lymphoproliferative
disorder, remains a challenge [1,2]. The ﬁrst pediatric ortho-
topic heart transplantation in the Center of Cardiovascular
and Transplantation Surgery in Brno was performed on a
10-year-old boy by J. Černý on May 24th, 1995. In this article,
we present the data obtained during more than 17 years of
follow-up of children who underwent HTx in our center.2. Patients and methods
The outcomes of HTx performed in the Center of Cardiovas-
cular and Transplantation Surgery in Brno between May 1995
and October 2012 in patients under 18 years of age were
analyzed retrospectively. The age of children listed for HTx
ranged between 2 months and 17.5 years (9.375.1 years), the
mean waiting time was 1067152.1 days. Twelve children
aged 2 months–14.8 years (5.775.2 years) did not survive to
undergo heart transplantation, their mean waiting time
was 141.67167.3 days. Children, who underwent HTx,
were 2.4–17.5 years (11.274.0 years) old and waited for
79.57136.9 days. All children, waiting for HTx, underwent
cardiac catheterization involving the assessment of cardiac
output and indexed pulmonary vascular resistance (PVRI). In
cases where PVRI was above 6WUxm2, reactivity of the
pulmonary vasculature was tested using alprostadil or nitric
oxide. Fixed PVRI above 6WUxm2 was considered to be a
contraindication to HTx [3].
Terminal heart failure due to dilated or restrictive cardi-
omyopathy was the most frequent cause leading to the
indication of HTx. Of the complex congenital heart anoma-
lies, HTx was performed in two patients suffering from failure
of systemic right ventricle, after the Senning-Mustard surgery
of uncorrected transposition and in double outlet of the right
ventricle (Table 1).
One patient was treated by intraaortic balloon contra-
pulsation (IABC) prior to HTx, 7 patients were treated with
inotropic support. Lymphocytotoxic test was positive in 3
patients. Biatrial heart transplantation technique was usedTable 1 – Indications for heart transplantation.
Died Excluded from
Dilated cardiomyopathy 8 2
Restrictive cardiomyopathy 2
Hypertrophic cardiomyopathy
Congenital heart anomalies 2 1
Total 12 3until 1996, bicaval technique has been used since 1996. The
time of cold graft ischemia ranged from 68 to 241 min
(167.6747.2 min). The age of donors was within the range of
2.4–36.8 years (17.579.0 years).2.1. Immunosuppression
Until 2002, the immunosuppressive treatment was based on
cyclosporine and azathioprine. Since 2003, cyclosporine and
mycophenolate mofetil have been used, tacrolimus and
mycophenolate mofetil represents an alternative for patients
with higher risk of rejection since 2008. Until 2002, induction
therapy consisted of anti-thymocyte globulin (ATG) admini-
strated for 5 post-operative days. IL-2R antagonists (daclizu-
mab, basiliximab) are given since 2003 on the day of surgery
and day 4 post-transplantation. We used steroid sparing
protocol, trying to discontinue corticosteroids in children by
one month after the transplantation[1]. Ganciclovir (acyclo-
vir) was administered prophylactically in all CMV-mismatch
patients for 3 months. Based on data from literature, for the
prophylaxis of Pneumocystis carinii infection we administered
trimethoprim–sulphamethoxazole for 3 months [4].2.2. Post-operative follow-up
Children who underwent heart transplantation were followed-
up in intervals ranging from 2 weeks to 3 months. Depending
on the time elapsed since HTx, clinical and echocardiographic
assessment, ECG evaluation and laboratory tests including
kidney and liver function evaluation and immunosuppressant
level measurement were performed. Hypertension treatment
was initiated in all patients with both systolic and diastolic
blood pressure measurements exceeding the 95th percentile of
range of norms for the given age [4]. We used the PCR method,
to detect and quantify the EBV and CMV load. During non-
invasive graft function monitoring, we performed the echo-
cardiographic evaluation of systolic and diastolic graft func-
tion, hypertrophy of the left ventricular posterior wall and
septum, the degree of atrioventricular valves regurgitation and
pericardial effusion [5]. Echocardiographic ﬁndings were
always compared to the previous ones. The suspicion of acute
rejection was based on clinical and echocardiographic ﬁndings
and subsequently conﬁrmed by endomyocardial biopsy (EMB).
Endomyocardial biopsies were evaluated according to the
ISHLT classiﬁcation [4]. Steroid pulses and conversion from
cyclosporine to tacrolimus were used during the ﬁrst post-
transplantation year to treat cellular rejection EMB ISHLT≥-
grade 1B or rejection EMB ISHLT≥grade 2 more than a year
post-HTx. Coronary angiography was performed as a part ofWL Transplanted Waiting Total
17 27
5 7
2 2
2 1 6
26 1 42
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The diagnosis of coronary graft disease was based on coronary
angiography ﬁndings, the morphology of coronary arteries and
on the comparison of the current and the previous ﬁndings.
Intracoronary ultrasonography (ICUS) was a part of coronary
angiography in patients older than 12 years During ICUS, the
increase of the maximum intimal thickening (MIT) was eval-
uated. Increase ≥0.5 mm/year was considered to be positive
ﬁnding [6].Fig. 1 – Long-term survival after HTx.
Table 3 – Incidence of rejections.
n2.3. Statistical analysis
Continuous data are characterized by the mean and standard
deviation. Categorical data are described using absolute and
relative values. Curves characterizing the survival of patients
and grafts were plotted using the Kaplan–Meier method and
Statistica software.Early rejection (≤1 year post-HTx) EMB ISHLT ≥grade I B 12
rejection after withdrawal of steroids 6
Late rejection (41 year post-HTx) EMB ISHLT ≥grade II 4
recurrent rejection 2
non-compliance 2
No treatment for rejection 6
No rejections 3
Table 4 – Incidence of infections.
n
Bacterial Sepsis 1
Bronchopneumonia 1
Viral CMV 4 (pneumonia 1)
EBV 5 (primo-infection 2)
Fungal Aspergillus
pneumonia
1
Protozoal Pneumocystis Jiroveci
pneumonia
13. Results
Heart transplantation was performed in 26 children aged
2.4–17.5 years (11.274.0 years). Five patients (19.2%) died
early after the HTx. The causes of death were cerebral
hypoxia with irreversible brain damage followed by the deve-
lopment of sepsis(2),progressing multiorgan failure despite
successful transplantation with favorable graft function in a
patient with advanced multiorgan failure before HTx(1),
acute steroid-resistant rejection(1) and early graft failure(1).
One patient died during the long-term follow-up, namely 6.5
years post-HTx because of late graft failure of unknown
etiology (Table 2). One-year, 5-year and 10-year post-HTx
survival rates are thus 81%, 81%, and 76.9%, respectively
(Fig. 1). The longest surviving patient underwent the trans-
plantation 17.5 years ago. One patient, who underwent
retransplantation 11.5 years after primary HTx(4.8%), survives
5.8 year after retransplantation.
Calcineurin inhibitors (CNI) are given to 15 patients, 14 of
them are taking tacrolimus. Six children were switched from
cyclosporine to tacrolimus during the treatment of rejection,
two because of hypertrichosis during cyclosporine therapy.
Two patients treated for PTLD were switched to mTOR-
inhibitors. Currently mTOR-inhibitors are a part of immuno-
suppressive treatment in 6 of our patients. With the use of
mTOR-inhibitor we experienced two adverse events (neutro-
penia and anemia) in two different patients. We have not had
to discontinue the therapy of mTOR-inhibitor in any of our
patients. Steroids were withdrawn in all children until 3Table 2 – Causes of death.
Early Late
Cerebral hypoxia, sepsis 2
Multiorgan failure 1
Steroid-resistant rejection 1
Early graft failure 1
Late graft failure 1
Total 5 (19.2%) 1 (3.8%)months after the transplantation. There was not any patient
on maintenance steroid therapy for one or more years
after HTX.
During the ﬁrst year after transplantation, 12 children
were treated for rejection ISHLT grade ≥1B; in 6 of them
rejection occurred after withdrawing the steroids. One
patient was treated with polyclonal antibodies for acute
steroid-resistant rejection with a hemodynamic response.
Four patients received therapy for late rejection (occurring
more than 1 year post-HTx), ISHLT grade ≥2. Of these,
2 patients suffered from recurrent rejection and 2 from
rejection following patient's non-compliance with the med-
ication. Six patients were never treated for rejection, 3 of
them never suffered from rejection grade≥1b (Table 3).
The most common infectious complications were viral
infections caused by CMV and/or EBV. Two patients were
treated for serious infections, one for Pneumocystis Jiroveci
pneumonia, the other for pneumonia caused by Aspergillus.
(Table 4). From the clinical point of view, repeated upper
airway infections are the most frequent problem; their course
is, however, usually benign.
Table 5 – Long-term morbidity.
Time since HTx 1
year
5
years
≥10
years
No. of patients 21 13 7
Hypertension (%) 23.8 66 71.4
Mild chronic kidney disease
(CKD2) (%)
23.8 23 28.6
Coronary graft disease (%) – 7.7 42.8
Lymphoproliferative disorder (%) – – 28.6
Hypoxic encephalopathy,
epilepsy (%)
9.5 – –
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 1 5 – e 3 1 9e318Hypertension is the most common morbidity, its inci-
dence is increasing with time elapsed since the transplanta-
tion. Antihypertensive medication is currently given to 12
patients. After repeated testing of renal functions (creatinine
levels and creatinine clearance adjusted for age), we con-
ﬁrmed mild chronic kidney disease (CKD2) in about one
quarter of children after HTx. The incidence of mild renal
insufﬁciency did not change signiﬁcantly during the long-
term follow-up. The renal insufﬁciency worsened temporarily
in 2 patients during an episode of infectious gastroenteritis
associated with dehydration.
Coronary graft disease was revealed in 4 grafts, with a
marked increase in its incidence 10 years after transplanta-
tion. The ﬁnding of severe coronary arteries disease asso-
ciated with decrease of the left ventricular ejection fraction
became an indication to re-transplantation 11 years after the
ﬁrst HTx in one patient; this patient now survives 5.7 years
after the re-transplantation. Dysfunction of the graft was
diagnosed echocardiographically in another patient 13 years
post-HTx. Coronary angiography revealed a signiﬁcant focal
narrowing of the left anterior descending branch, which was
managed using PCI with implantation of 2 DES stents. Mild
LAD stenosis demonstrated only by ICUS, were detected in
another 2 patients with favorable graft function.
Two patients developed the late form of post-transplant
lymphoproliferative disorder (PTLD) 8 and 15 years after HTx
(B-cell lymphoma, Hodgkin's disease). Signiﬁcant EBV load
was noted in both of these patients before PTLD develop-
ment. EBV primo-infection was diagnosed 15 years post-HTx
in a patient transplanted at the age of 2 years. Both patients
survive 6.5 and 1 year after PTLD diagnosis was deﬁned.
As for neurological complications, one patient has a mild
hemiparesis caused by cerebral hypoxia. Another patient is
treated for epilepsy (Table 5).4. Discussion
Low age, the length of waiting time and limited treatment
possibilities of terminal heart failure were risk factors for
mortality in our group of children waiting for HTx. The lack
of organs represents a permanent and global problem, con-
cerning especially the youngest children [1,7]. Patient survival
after HTx is inﬂuenced by age at the time of transplant,
diagnosis, era of transplant and other factors. Early mortality
in our group of pediatric heart recipients was inﬂuenced by our
lack of experience including indications for HTx, perioperativeand early post-operative care during the initial years. However
since 2000 no patient died soon after transplantation.
Rejection and infection are persistent post-transplant
risks especially in the ﬁrst year after HTx. The development
of new immunosuppressive agents and their introduction to
the treatment of children after HTx have led to the decrease
in incidence of rejection episodes [2,8]. In 2002 we changed
our protocol because of side effect of ATG induction therapy
(thrombocytopenia), interleukin-2 receptor antagonist were
well tolerated by our pediatric recipients. The ISHLT registry
data 2011 demonstrated increasing number of centers using
induction, tacrolimus and mycophenolate mofetil in pediatric
heart recipients. However there is still a signiﬁcant number of
patients (66%) receiving steroids as a part of maintenance
immunosuppressive regimens at the 1-year follow-up. This
fact probably reﬂects the management strategy of a previous
era before efforts to eliminate corticosteroids in children after
HTx. [4,7]. Since the beginning of our pediatric transplant
program we have used steroid sparing protocol to reduce the
harmful effect of steroids in children. It is of interest to note,
that 28.6% of our long-term survivors have never had a
treatable episode of rejection. Inhibitors of the mammalian
target of rapamycin have not yet assumed a major place as
adjunctive agents in children. There are no data to support its
use as a primary immunosuppressant after pediatric HTx
in lieu of a CNI. Pediatric use has focused on its role as a
CNI-sparing agent late after transplantation [9,10]. Experi-
mental data suggest that inhibitors of mTOR may reduce
graft vasculopathy [7,9]. The effect of mTOR-inhibitors is
tested as a part of treatment of PTLD [11]. We used mTOR-
inhibitor as a part of immunosuppressive regimen late after
transplantation in 6 patients (1 sirolimus and 5 everolimus),
only two of them have CNI-free regimen.
Increasing time after heart transplantation, recipient and
donor age, as well as the history of rejection episodes are
important risk factors for the development of coronary graft
disease also in pediatric recipients [2,4,7]. The 2011 ISHLT
Report demonstrated a linear decrease in freedom from
coronary graft disease from time of transplant with 60% of
patients free of coronary graft disease 11 years after HTX. In
our group of children was the incidence of coronary graft
disease 7.7% by 5 years after HTX and 42.8% by 10 and more
years after transplantation. In both patients with severe,
symptomatic cardiac allograft vasculopathy the disease
developed rapidly. One of them, who underwent retransplan-
tation (5%), had a history of late rejection episodes because of
non-compliance with the medication. In the ISHLT pediatric
heart transplantation Report 2011 retransplantations account
for 6% of transplant operations.
There is a linear decrease in freedom from malignancy
from time of transplant with malignancy having developed in
15% of pediatric patients by 13 years. Almost all malignancies
were lymphomas [7]. An association was demonstrated
between primo-infection with EBV and development of PTLD
in children after organ transplantations [7,11–13]. In our
group of pediatrics heart recipients 2 patients (10%) devel-
oped late form PTLD.
None of our pediatric patients developed severe renal
dysfunction after transplantation compared with 10% of
patients in the ISHLT report [7].
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similar to those in adults, however a major difference is in
the risk of signiﬁcant coronary graft disease, which is less
prevalent in children In addition neoplasm is a more common
cause of death in adult long-term survivors after HTx [4,7].
Our results reﬂect small center volume associated
increased risk of 1-year mortality [7]. The data of ISHLT
registry 2011 demonstrated about 60% survival 10 years after
HTx inﬂuenced by age at the time of transplantation. Risk
factors of long-term mortality include retransplantation,
congenital heart defects and center volume [7]. We conﬁrm
that long-term survival is achievable after pediatric heart
transplantation. There was only 1 late death in 16-year-old
patient who underwent HTx after repeated correction of
congenital heart disease. All other patients have been surviv-
ing, long-term survival in our group of patients is 76.9%.
However the quality of life of patients who underwent HTx
during childhood is being affected by increasing incidence of
post-transplantation morbidities, primarily coronary graft
disease. Both long-term physical and mental development
of children after HTx is favorable. The great majority of our
pediatric patients attended or attends school and participates
in everyday activities without any problems. Non-compliance
of adolescents with the medication and recommended
regime is a permanent problem [1,14].5. Conclusion
Heart transplantation has become an effective treatment of
terminal heart failure in childhood. Improvement in HTx
outcomes in children are driven especially by the decrease
in early mortality, late morbidity has not changed in the past
two decades. Coronary graft disease still represents the most
prominent risk for late mortality in children after HTx. Our
conclusions are limited by the size of our pediatric patients'
population.
r e f e r e n c e s
[1] M. Heubler, S. Schubert, H.B. Lehmkuhl, et al., Pediatric heart
transplantation: 23-year single-center experience, European
Journal of Cardio-Thoracic Surgery 39 (2011) 83–89.[2] D.L. Morales, W.J. Dreyer, S.W. Denﬁeld, et al., Over two
decades of pediatric heart transplantation: how has survival
changed?, Journal of Thoracic and Cardiovascular Surgery
133 (2007) 632–639.
[3] B. Daftari, J.C. Alejos, G. Perens, Initial experience with
sildenaﬁl, bosentan and nitric oxide for pediatric
cardiomyopathy patients with elevated pulmonary vascular
resistance before and after orthotopic heart transplantation,
Journal of Transplantation 3 (2010) 426–435.
[4] M. Ross, P. Kouretas, P. Gamberg, et al., Ten- and 20-year
survivors of pediatric orthotopic heart transplantation,
Journal of Heart and Lung Transplantation 25 (2006) 261–269.
[5] L. Almenar, A. Osa, L. Martinez-Dolz, Echocardiographic
evaluation of the evolutionary changes after heart
transplantation, Transplantation Proceedings 38 (2006)
2575–2579.
[6] M.R. Mehra, M.G. Crespo-Leiro, A. Dipchand, et al.,
International Society for Heart and Lung Transplantation
working formulation of a standardized nomenclature for
cardiac allograft vasculopathy–2010, Journal of Heart and
Lung Transplantation 29 (2010) 717–727.
[7] R. Kirk, L.B. Edwards, A.Y. Kucheryavaya, et al., The Registry
of the International Society for Heart and Lung
Transplantation: Fourteenth Pediatric Heart Transplantation
Report–2011, Journal of Heart and Lung Transplantation 30
(2011) 1095–1103.
[8] S. Nobuyuki, M. Chan, H. Valantine, et al., Analysis of
survivors more than 10 years after heart transplantation in
the cyclosporine era: Stanford experience, Journal of Heart
and Lung Transplantation 23 (2004) 128–134.
[9] C.A. Irving, S.A. Webber, Immunosuppression therapy for
pediatric heart transplantation, Current Treatment Options
in Cardiovascular Medicine 12 (2010) 489–502.
[10] J. Herman, P. Vandenberghe, I. van den Heuvel, et al.,
Successful treatment with rituximab of lymphoproliferative
disorder in a child after cardiac transplantation, Journal of
Heart and Lung Transplantation 21 (2002) 632–635.
[11] S. Schubert, H. Abdul-Khaliq, H.B. Lehmkuhl, Diagnosis and
treatment of post-transplantation lymphoproliferative
disorder in pediatric heart transplant patients, Pediatric
Transplantation 13 (2009) 54–62.
[12] S.A. Webber, D.C. Naftel, F.J. Fricker, et al.,
Lymphoproliferative disorders after pediatric heart
transplantation: a multiinstitutional study, Lancet 367 (2006)
233–239.
[13] A. Gambino, A. Cerutti, G. Feltrin, et al., Outcome after
pediatric heart transplantation: two decades of a single
center experience, European Journal of Cardio-Thoracic
Surgery 32 (2007) 220–224.
